



For Immediate Release

Aciont[®] Strengthens Management Team with Industry Leader in Ophthalmic Product Development

Balbir Brar brings 25 years of drug and device development experience to Aciont Inc.

Salt Lake City, UT – April 2, 2010 – Aciont Inc. today announced the appointment of Balbir Brar, D.V.M, and Ph.D., to be Vice President, Research and Development. Dr. Brar will oversee the development of Aciont's Visulex[®] non-invasive, drug delivery system to treat sight threatening diseases of the back of the eye.

“We are pleased to bring Dr. Balbir Brar—a successful industry leader in ophthalmic research and development who at one time supervised concurrently more than 20 pharmaceutical product development projects—on board to the Aciont team,” said John Higuchi, Aciont's CEO. “Bal will be instrumental in keeping Aciont focused on achieving our product development milestones efficiently and targeting the important unmet patient and physician needs of our industry.” Dr. Brar has extensive first hand experience of how to design studies to move products through development rapidly while anticipating what can go wrong and what the FDA expects.

Dr. Brar joins Aciont with an extensive background of drug and device pharmaceutical development. For the past six years he has worked as an independent consultant in the drug development field as chief scientific officer/board member for the start-up of various pharmaceutical development ventures. Prior to this, Dr. Brar worked for Allergan Pharmaceutical where he played a major role in the approval of eight major drugs currently on the market including: Alphagam[®], Lumigan[®], Restasis[®], and Botox[®]. Dr. Brar also contributed to the development of blockbuster drugs at SmithKline & Beckman and Lederle/Wyeth. Dr. Brar has a Ph.D. in Toxicology/Pathology from Rutgers University and D.V.M. from India with finance training from Harvard Business School.

Aciont Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic), controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont's goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance. Aciont is located in Salt Lake City, Utah. For more information, visit the company's website at www.aciont.com.

Source: Aciont Inc.

Contact

John Higuchi, CEO

Aciont, Inc.

(801) 359-3461

admin@aciont.com